Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163267
Status:
COMPLETED
Last Update Posted:
2011-08-09
First Post:
2005-09-08
Brief Title:
Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel
Sponsor:
University Hospital Tuebingen
Organization:
University Hospital Tuebingen
Study Overview
Official Title:
Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study
Status:
COMPLETED
Status Verified Date:
2007-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Mirror Study is a randomized double-blinded mono-centre trial the access the periinterventinal and postinterventional administration of clopidogrel in patients with peripheral vascular disease
Detailed Description:
Clopidogrel is approved for secondary prevention of atherosclerosis in patients with peripheral vascular disease Currently there are no data about the amount of platelet activation during peripheral arterial intervention the effect of clopidogrel on platelet adhesion and its clinical impact
Patients with chronic peripheral arterial disease receive placebo or clopidogrel before the intervention and for 6 months in follow-up Platelet activation the effect on macro-and microcirculation will be assessed as well as clinical endpoints
Patients with chronic peripheral arterial disease receive placebo or clopidogrel before the intervention and for 6 months in follow-up Platelet activation the effect on macro-and microcirculation will be assessed as well as clinical endpoints
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D3100340 | None | None | None |